A therapeutic option that prevents hospitalization is essential
Uma terapia com anticorpos monoclonais, já aprovada no Brasil para tratar casos leves e moderados de COVID-19, revelou agora uma capacidade preventiva expressiva: uma única dose reduziu em 81,6% o risco de doença sintomática ao longo de oito meses. O estudo, conduzido com quase 2.500 pessoas em situação de alto risco, reacende o debate sobre como sistemas de saúde pública podem incorporar inovações científicas quando a logística e os custos impõem seus próprios limites. No Brasil, onde a aprovação regulatória existe mas o acesso pelo SUS permanece incerto, o caso do Regn-Cov2 coloca em relevo uma tensão antiga: a distância entre o que a ciência pode oferecer e o que as instituições conseguem entregar.
- Para populações que não respondem adequadamente às vacinas — idosos e imunossuprimidos — a ausência de alternativas preventivas representa um risco real e contínuo.
- A Conitec rejeitou a incorporação inicial do medicamento ao SUS em julho, apontando limitações nos estudos e a dificuldade prática de administrar a infusão dentro da janela terapêutica exigida.
- A Roche prepara nova submissão à Anvisa para uso preventivo, enquanto uma segunda consulta pública permanece aberta até 3 de dezembro, mantendo viva a possibilidade de reversão.
- A análise econômica da própria Conitec projeta economia anual de R$ 804 milhões com a prevenção de hospitalizações em grupos vulneráveis, tornando o argumento financeiro difícil de ignorar.
- O medicamento já tem aprovação preventiva em mais de 50 países, mas no Brasil a estratégia da Roche de negociar exclusivamente com governos torna o acesso privado indisponível, concentrando tudo na decisão pública.
Um medicamento de anticorpos monoclonais aprovado no Brasil para tratar COVID-19 leve e moderada ganhou um novo capítulo: um estudo recente demonstrou que uma única dose do Regn-Cov2 — combinação de casirivimabe e imdevimabe, desenvolvida pela Roche em parceria com a Regeneron — reduziu em 81,6% o risco de doença sintomática ao longo de oito meses. O ensaio acompanhou 2.475 pessoas que conviviam com alguém infectado e ainda não tinham contraído o vírus, cada uma recebendo 600 mg de cada anticorpo.
A descoberta levou a Roche a preparar uma nova solicitação à Anvisa para uso preventivo do medicamento. Atualmente, a agência autoriza o Regn-Cov2 apenas para pacientes a partir de 12 anos já infectados e com risco elevado de agravamento — proibindo seu uso em hospitalizados ou em ventilação mecânica, dado que estudos anteriores indicaram ausência de benefício e possível piora nesses casos.
No plano internacional, o medicamento já tem aprovação preventiva em mais de 50 países. No Brasil, porém, o caminho é mais tortuoso. A Roche optou por negociar exclusivamente com governos, sem disponibilizar o produto em canais privados. Desde abril, a empresa dialoga com o Ministério da Saúde sobre incorporação ao SUS. A Conitec rejeitou o pedido inicial em julho, alegando limitações nos estudos publicados e dificuldades logísticas para administrar a infusão dentro do prazo necessário após o contato com o vírus. Uma segunda consulta pública está aberta até 3 de dezembro.
O argumento econômico, no entanto, pesa na balança: a própria análise técnica da Conitec estima que tratar idosos e imunossuprimidos — grupos com resposta vacinal frequentemente insuficiente — poderia gerar economia anual de cerca de R$ 804 milhões em hospitalizações evitadas. Mauricio Rocha, gerente médico da Roche para COVID-19 no Brasil, reconhece que a vacinação segue sendo a principal ferramenta de combate à pandemia, mas defende que, para quem não desenvolve imunidade adequada, uma opção preventiva pode ser decisiva. A ciência avançou; resta saber se a estrutura pública conseguirá acompanhá-la.
A monoclonal antibody treatment already approved in Brazil for treating mild to moderate COVID-19 has now demonstrated a second life: preventing the disease altogether. The drug, called Regn-Cov2, is a combination of two antibodies—casirivimabe and imdevimabe—developed through a partnership between pharmaceutical giant Roche and the research firm Regeneron. In a new study released this month, a single injection of the cocktail reduced the risk of developing symptomatic COVID-19 by 81.6 percent over an eight-month period.
The trial enrolled 2,475 people who did not yet have COVID but faced high risk of infection because they lived with someone who did. Each participant received a dose of 600 milligrams of casirivimabe and 600 milligrams of imdevimabe—the same dosage used in earlier trials for patients already sick with the virus. Mauricio Rocha, the medical manager overseeing Roche's COVID-19 portfolio in Brazil, explained that researchers tracked participants for a month initially, then continued monitoring to confirm the protection held. Over eight months, the results were clear: one dose offered substantial shield against symptomatic illness.
The finding has prompted Roche to prepare new paperwork for Brazil's health regulator, Anvisa, seeking approval to use the drug as a preventive treatment. Currently, Anvisa permits Regn-Cov2 only for patients aged twelve and older who already have COVID and face high risk of severe disease. The agency explicitly prohibits its use in hospitalized patients or those requiring high-flow oxygen or mechanical ventilation—a restriction based on earlier clinical data showing the antibodies offered no benefit and may have worsened outcomes in that population.
Roche has already secured approval for preventive use in more than fifty countries, including the United States, United Kingdom, Canada, Japan, India, Australia, Israel, and Switzerland. In Brazil, however, the path forward is more complicated. The company has pursued a strategy of negotiating exclusively with governments rather than making the drug available through private channels. Since April, Roche has been in dialogue with Brazil's Ministry of Health about incorporation into the public health system.
A public consultation was opened through Conitec, the commission responsible for evaluating new technologies for Brazil's unified health system, but the initial request was rejected in July. The commission cited "limitations in published studies" and flagged a critical logistical problem: the narrow window between symptom onset and drug infusion makes real-world implementation difficult in clinical practice. A second process began after an internal request from the Ministry of Health's secretariat for science, technology, innovation, and strategic health inputs. The public now has until December 3 to submit comments.
Yet the economic case is substantial. Conitec's technical analysis projected that treating elderly and immunocompromised patients—those most likely to have weak vaccine responses—could generate annual savings of approximately 804 million Brazilian reais by preventing hospitalizations. Rocha acknowledged that vaccination remains the cornerstone of pandemic response but emphasized that a meaningful segment of the population does not mount adequate immune responses to vaccines. For those patients, he argued, a therapeutic option that prevents hospitalization is essential.
The drug sits at an intersection of medical innovation and public health infrastructure. The science is proven. The regulatory framework exists. What remains uncertain is whether Brazil's health system can absorb and deploy it efficiently enough to justify the cost—and whether the government will decide the investment is worth making.
Citas Notables
It is very important that there exists a therapeutic option for patients who do not respond adequately to vaccines. This treatment is needed to prevent hospitalization.— Mauricio Rocha, medical manager of Roche's COVID-19 portfolio in Brazil
La Conversación del Hearth Otra perspectiva de la historia
Why does this drug need a separate approval for prevention when it's already approved for treatment?
Because prevention and treatment are different clinical scenarios. The drug was tested and approved for people already sick with COVID. Using it before someone gets sick—even if they're at high risk—is a different medical claim that requires its own evidence and regulatory review.
The study shows 81.6% effectiveness. That sounds very high. Is that reliable?
It's a solid number from a reasonably large trial of 2,475 people. But the commission in Brazil raised a real concern: the drug has to be given within a narrow window after exposure, which is logistically hard in practice. A perfect study result doesn't always translate to real-world success.
Why is Roche only negotiating with governments, not selling it privately?
That's a business strategy. By dealing only with governments, they control distribution, pricing, and narrative. It also positions them as a partner in public health rather than a profit-driven vendor. But it means the drug sits unused in Brazil even though it's approved.
The economic analysis mentions 804 million reais in savings. Does that mean it's definitely worth buying?
Not necessarily. That's a projection based on assumptions about who would use it and how many hospitalizations it would prevent. The commission still said no, partly because they weren't convinced the logistics would work and partly because they wanted more evidence.
Who benefits most from this drug if it gets approved?
Older people and immunocompromised patients—those whose vaccines don't work well. For them, this could be the difference between staying healthy and ending up in the hospital. That's why the economic case focuses on those groups.
What happens next?
Roche submits new paperwork to Anvisa. The commission reviews it again. The public comments by December 3. Then Brazil decides whether prevention is worth the cost and complexity.